James Nagarajah - Concepedia

Author

James Nagarajah

Also Known As

H. Lahner, J Nagarajah, J. Farahati, J. Nagarajah, JAMES NAGARAJAH, James Nagarajah, Nagarajah, J, Nagarajah, J., Nagarajah, James, T. Dannat

206

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center University of Duisburg-Essen Essen University Hospital Erasmus MC

About

James Nagarajah is an author at Radboud University Nijmegen specializing in medicine, nuclear medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	984
2	Health Sciences	13	13	645
3	Engineering	6	6	316
4	Public Health	2	2	75
5	Biostatistics	1	1	34

James Nagarajah

Publications

Citations

H-Index

Page 1

	Year	Citations
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial Michael J. Morris, Daniel Castellano, Ken Herrmann, The Lancet UrologyOncologyGenitourinary Cancer177Lu-psma-617 VersusMedicine	2024	189
Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma Florian Grabellus, James Nagarajah, Andreas Bockisch, Clinical Nuclear Medicine	2012	144
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine James Nagarajah, Mina Le, Jeffrey A. Knauf, Journal of Clinical Investigation EngineeringErk InhibitionTumor BiologyBraf-mutant Thyroid CancerOncology	2016	134
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial Karim Fizazi, Ken Herrmann, Bernd J. Krause, The Lancet Oncology UrologyHealth-related QualityPain MedicinePain OutcomesMedicine	2023	101
Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer Lino M. Sawicki, Johannes Grueneisen, Benedikt M. Schaarschmidt, European Journal of Radiology Medical ImagingMedicinePet-mriWhole-body StagingRecurrent Breast Cancer	2015	97
Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by <sup>18</sup>F-FDG PET: Feasibility of a Metabolic Grading System Samer Ezziddin, Linda Adler, Amir Sabet, Journal of Nuclear Medicine	2014	96
Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer Johannes Grueneisen, James Nagarajah, Christian Buchbender, Investigative Radiology	2015	94
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate Amir Sabet, Khaled Ezziddin, Ulrich‐Frank Pape, European Journal of Nuclear Medicine and Molecular Imaging Renal FunctionMedicineRadiopharmaceutical TherapyPharmacotherapyNephrology	2013	89
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study Bastiaan M. Privé, Steffie M. B. Peters, Inge M. van Oort, Clinical Cancer Research	2021	89
Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using <sup>124</sup>I PET Imaging Walter Jentzen, Jan Hoppenbrouwers, Paul van Leeuwen, Journal of Nuclear Medicine	2014	88

Page 1